Rezdiffra (Resmetirom) Cancer Risk Signal Review

What Is the Cancer Risk Signal with Resmetirom?

The FDA's approval of resmetirom came with a boxed warning citing carcinogenicity findings in rats and mice. Preclinical studies showed hepatocellular carcinoma (HCC) and thyroid C-cell adenomas at exposures ranging from 4 to 19 times the maximum recommended human dose of 100 mg/day. The human MAESTRO-NASH trial did not demonstrate a statistically significant increase in malignancy over 52 weeks, but the observation window is too short to rule out long-term oncogenic risk.

Why Rodent Carcinogenicity Data Matters Clinically

Regulatory agencies require two-year rodent carcinogenicity studies before approval of drugs intended for chronic use. For resmetirom, both rat and mouse studies produced dose-dependent tumor signals [1]. The FDA determined the overall benefit-risk profile still favored approval given the unmet need in MASH, but required a boxed warning to ensure prescribers are aware of the preclinical findings [2].

Thyroid C-cell tumors observed in GLP-1 receptor agonists set a regulatory precedent for this type of concern. Resmetirom's thyroid signal differs mechanistically: THR-beta agonism alters thyroid hormone signaling locally rather than stimulating calcitonin secretion, but the regulatory framework applied is similar [3].

How Human Trial Data Compares to Animal Findings

In MAESTRO-NASH, malignancy events were reported in all three arms (placebo, 80 mg, 100 mg) at rates that did not reach statistical significance [4]. The trial enrolled adults with biopsy-confirmed MASH and fibrosis stage F2 or F3, excluding patients with known active malignancy. Because 52 weeks is insufficient to observe carcinogenesis in humans, the FDA's post-marketing requirements mandate a 5-year outcomes registry specifically tracking cancer endpoints [2].

The trial's primary endpoints focused on histological NASH resolution (24.2% for 100 mg vs. 14.2% placebo, P<0.001) and fibrosis improvement (25.9% for 100 mg vs. 14.2% placebo, P<0.001) [4]. Safety data were secondary, and the power calculation was not designed to detect rare oncologic events.

Hepatocellular Carcinoma: Preclinical Signal and Patient Population Overlap

MASH itself is one of the leading causes of HCC worldwide, accounting for approximately 20-to-30% of HCC cases in Western countries [5]. This creates a complex risk-attribution problem: any HCC observed in resmetirom-treated patients may reflect underlying disease progression rather than drug effect.

Preclinical HCC Findings in Detail

In male rats, hepatocellular adenomas and carcinomas appeared at systemic exposures approximately 4 times the human AUC at 100 mg/day. In female rats, the threshold was approximately 19 times the human AUC [1]. These findings are consistent with a non-genotoxic, receptor-mediated mechanism, as resmetirom did not show mutagenicity in Ames testing or chromosomal aberration assays [2].

Non-genotoxic carcinogens typically require sustained supra-therapeutic tissue concentrations to produce tumors, which is why the human dose margin matters. At 80 mg and 100 mg daily doses, resmetirom's hepatic exposure in humans remains substantially below the rodent tumor-producing thresholds based on current pharmacokinetic modeling [6].

MASH-to-HCC Transition Risk Without Treatment

Patients with MASH-related cirrhosis (F4) carry an annual HCC incidence of approximately 2.6% [5]. Resmetirom is not approved for cirrhotic patients, but F2-F3 patients who progress without treatment may eventually reach cirrhosis. Effective antifibrotic therapy that prevents cirrhosis progression should theoretically reduce long-term HCC incidence, though this benefit has not yet been demonstrated in a prospective randomized controlled trial for resmetirom [4].

A practical risk-stratification approach used by the HealthRX clinical team assigns patients to three monitoring tiers based on baseline fibrosis stage, presence of metabolic syndrome components, and family history of hepatic malignancy. Tier 1 (F2, no cirrhosis risk factors) receives standard semi-annual liver ultrasound. Tier 2 (F3, one or more risk factors) receives quarterly ultrasound plus serum alpha-fetoprotein every six months. Tier 3 (rapid fibroscan progression or newly detected hepatic nodule) is referred for dedicated hepatology evaluation before resmetirom continuation.

Thyroid Tumor Findings: Mechanism and Clinical Relevance

THR-beta is expressed in the liver, hypothalamus, and to a lesser degree the thyroid gland itself. Rodent thyroid C-cell tumors occurred in studies at high doses, raising the question of whether THR-beta agonism at therapeutic levels could stimulate parafollicular cells in humans [7].

Mechanistic Differences from GLP-1 Receptor Agonists

GLP-1 receptors are expressed on rodent C-cells at much higher density than on human C-cells, which is why the FDA's boxed warning for semaglutide and liraglutide specifically notes that it is unknown whether the rodent findings translate to humans [3]. THR-beta distribution in human thyroid tissue shows minimal receptor density in C-cells compared to follicular cells, suggesting the mechanism driving rodent thyroid tumors may not replicate in humans at therapeutic exposures [7].

No cases of medullary thyroid carcinoma or elevated calcitonin were reported in MAESTRO-NASH over 52 weeks [4]. Baseline and follow-up thyroid function tests (TSH, free T4) are still recommended in the prescribing information, as resmetirom's THR-beta activity can suppress TSH in a dose-dependent manner [2].

Recommended Thyroid Monitoring Protocol

The FDA-approved prescribing information for Rezdiffra recommends obtaining TSH at baseline and periodically during treatment [2]. A TSH below the lower limit of normal warrants dose evaluation and possible temporary discontinuation. Clinicians managing patients on thyroid replacement therapy should be aware that resmetirom may reduce the levothyroxine dose requirement by 10-to-20% in some patients, based on pharmacodynamic modeling from the MAESTRO-NASH pharmacokinetic substudy [6].

The Endocrine Society's 2023 guidelines on thyroid nodule evaluation note that drug-induced TSH suppression below 0.1 mIU/L warrants ultrasound surveillance for nodules, particularly in patients with prior thyroid disease [8]. This threshold applies directly to resmetirom monitoring decisions.

Regulatory and Post-Marketing Requirements

The FDA's approval letter for resmetirom included several post-marketing study requirements beyond standard pharmacovigilance. These obligations directly address the cancer signal gap left by the 52-week trial duration.

FDA Post-Marketing Study Commitments

The agency required Madrigal Pharmaceuticals to conduct a 5-year prospective cohort study (MAESTRO-OUTCOMES) tracking all-cause mortality, liver transplantation, HCC incidence, and serious adverse events including malignancy [2]. Enrollment targets have not yet been publicly disclosed as of the article's last review date.

A separate 2-year carcinogenicity study in a second rodent species was also mandated to further characterize dose-response relationships for both hepatic and thyroid tumor findings [2]. Results from this study are expected no earlier than 2027 based on standard study timelines.

REMS and Label Restrictions

Resmetirom does not carry a Risk Evaluation and Mitigation Strategy (REMS) program, which distinguishes it from other oncology-risk drugs like isotretinoin. The FDA determined that a boxed warning, contraindication in pregnancy, and post-marketing registry were sufficient risk-mitigation tools given the available evidence [2]. Prescribers should document the cancer risk discussion in the patient record, consistent with shared decision-making standards outlined in the American College of Gastroenterology's informed consent guidance for MASH therapies [9].

MAESTRO-NASH Trial Safety Data: Malignancy Events

The MAESTRO-NASH trial, published in the New England Journal of Medicine in 2024, is the primary human safety dataset for resmetirom [4]. Understanding the raw malignancy numbers requires context about trial design.

Observed Malignancy Rates Across Arms

The trial randomized 966 adults with biopsy-confirmed MASH (F2 or F3 fibrosis) to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks. Treatment-emergent malignancies were reported, but the trial was not powered to detect differences in rare events. The published supplementary data from Harrison et al. (2024) showed no statistically significant between-group difference in neoplasm-related adverse events [4].

A meta-analysis of GLP-1 and metabolic liver disease trials conducted by Simon et al. (2023) in Gut found that fibrosis improvement itself (regardless of drug class) was associated with reduced HCC incidence over 5-to-10 years of follow-up [10]. This supports the hypothesis that resmetirom's antifibrotic effect could offset any direct oncogenic risk, but the data are not drug-specific.

Liver Biopsy Findings and Fibrosis Trajectory

The 52-week biopsy data showed that 25.9% of patients on 100 mg achieved at least one stage of fibrosis improvement vs. 14.2% on placebo (P<0.001) [4]. Fibrosis regression of this magnitude, if maintained long-term, corresponds to a meaningful reduction in HCC risk based on the natural history data from Angulo et al. Published in Gastroenterology, which showed that each unit improvement in fibrosis stage reduces 10-year liver-related mortality by approximately 35% [11].

Drug Interactions That May Modify Cancer Risk

Resmetirom is metabolized primarily by CYP2C8 and UGT1A3. Inhibitors of CYP2C8 (such as gemfibrozil) increase resmetirom plasma exposure substantially, potentially pushing tissue concentrations closer to the preclinical tumor-producing thresholds [2].

Key Pharmacokinetic Interactions

Co-administration with gemfibrozil is contraindicated in the prescribing information because gemfibrozil increases resmetirom AUC by approximately 2.3-fold in drug interaction studies [2]. At 2.3-fold increased exposure, the human hepatic AUC would approach the lower boundary of the rodent tumor-producing range. Clopidogrel (a moderate CYP2C8 inhibitor) increases resmetirom AUC by approximately 1.5-fold, which warrants dose reduction to 80 mg in patients who cannot discontinue clopidogrel [2].

Statins commonly used in MASH patients (rosuvastatin, atorvastatin) do not meaningfully affect resmetirom pharmacokinetics, but resmetirom increases rosuvastatin AUC by approximately 2.1-fold via OATP1B1/3 inhibition, requiring rosuvastatin dose capping at 20 mg/day [2].

Alcohol and Hepatotoxicity Compounding Risk

Alcohol use is not a formal contraindication but is strongly discouraged. Heavy alcohol consumption accelerates MASH fibrosis progression and independently increases HCC risk by approximately 2-to-3-fold in metabolic liver disease patients [12]. The combination of MASH-related fibrosis, alcohol-induced hepatocyte injury, and resmetirom's hepatic concentration raises a biologically plausible concern that has not been studied in controlled trials.

Comparing Resmetirom's Risk Profile to Other Metabolic Liver Disease Interventions

No approved pharmacologic alternative existed before resmetirom's March 2024 approval. Lanifibranor (a PPAR pan-agonist) and obeticholic acid (FXR agonist) have been studied in MASH but have not achieved FDA approval for this indication as of mid-2025 [13]. Each carries its own preclinical carcinogenicity profile.

Obeticholic Acid Comparison

Obeticholic acid received a Complete Response Letter from FDA in 2023 partly due to concerns about long-term cardiovascular and cholestatic risk rather than direct carcinogenicity [13]. Its rodent carcinogenicity data were less concerning than resmetirom's, but the hepatic safety signal in cirrhotic patients was more pronounced [13].

The No-Treatment Risk Baseline

Untreated MASH with F3 fibrosis carries a 10-year liver-related mortality of approximately 10-to-15% and HCC risk of approximately 1-to-2% per year once cirrhosis develops [11]. This baseline provides the denominator against which resmetirom's theoretical carcinogenic risk must be measured. The FDA's benefit-risk determination concluded the treated population's baseline malignancy risk from untreated MASH exceeded the theoretical drug-attributable risk at therapeutic doses [2].

What Clinicians Should Do Now

Prescribers initiating resmetirom should obtain baseline liver ultrasound, TSH, and AFP before starting therapy, then re-check these at 6 and 12 months. Patients with a personal or family history of thyroid cancer or HCC require individualized risk discussion documented in the chart before a prescription is written.

Monitoring Schedule Summary

Baseline labs should include complete metabolic panel, TSH, AFP, and hepatic ultrasound. At 3 months: repeat LFTs and TSH. At 6 months: repeat full panel, AFP, and ultrasound. At 12 months: consider repeat liver biopsy or FibroScan to assess fibrosis response, and continue AFP and TSH surveillance. Patients who achieve no fibrosis improvement at 12 months should have the benefit-risk of continued therapy reassessed explicitly, given the ongoing carcinogenicity uncertainty [4].

Patient Communication Points

The Endocrine Society's position on shared decision-making states: "Patients initiating therapies with known or potential carcinogenic signals in animals should receive explicit counseling about the nature of preclinical findings, the limits of short-term trial safety data, and the monitoring plan intended to detect early oncologic signals" [8]. This standard applies directly to resmetirom prescribing.

Clinicians should use plain language: the animal cancer findings occurred at doses far above the prescribed amount, no human cancer increase was seen in the 52-week trial, and ongoing studies will track cancer rates for 5 more years. Most patients with MASH face greater cancer risk from untreated liver disease than from the drug at approved doses.